Skip to main content

Table 1 Characteristics of the studies included in the network meta-analysis

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Study IDTreatment 1Treatment 2Style
nAge (years)InterventionReceptor statusPrior therapynAge (years)InterventionReceptor statusPrior therapy
MedianRangeER+/PR+TNChemoHormonoMedianRangeER+/PR+TNChemoHormono
Norikazu Masuda 2017 [7]245332–78Bev + Tax222915306028–71Tax2461319RCT
David Miles 2017 [8]2395528–85Bev + Tax20039116922425628–77Tax20339118105RCT
Christoph Rochlitz 2016 [19]716430–82Bev + Tax611038NA686229–81Bev + Cap+Cyc521537NARCT
Christoph Zielinski 2016 [12]266NANABev + Tax2056014250265NANABev + Cap2016414343RCT
A. Welt 2016 [16]2956334–88Bev + Cap+Vin233611951692976129–85Bev + Cap23661193171RCT
O. Trédan 2016 [20]585635–77Bev + Exm5713533595535–86Bev + Tax5903839RCT
Denise A. Yardley 2015 [17]566130–77Bev + Tax+Exr44123434575725–79Bev + Tax45123137RCT
Veronique Dieras 2015 [18]565732–75Bev + Tax+Tre45910NA585231–74Bev + Tax451211NARCT
Hans-Joachim Luck 2015 [15]1115731–78Bev + Tax+Cap1110NANA1165731–80Bev + Tax1160NANARCT
S.W. Lam 2014 [13]1565632–76Bev + Tax+Cap1332390821565634–74Bev + Tax132248976RCT
Joseph Gligorov 2014 [14]914924–80Bev + Tax+Cap6625NANA945424–77Bev + Tax7321NANARCT
Istvan Lang 2013 [11]2795948–65Bev + Cap212671761712855949–64Bev + Tax22263180175RCT
Adam M. Brufsky 2011 [21]2015628–86Bev + Tax14547NANA1035635–84Tax7720NANARCT
975731–78Bev + Cap7418NANA475023–90Cap3610NANARCT
Miguel Martin 2011 [22]975544–66Bev + Tax78196464945343–63Tax75196256RCT
915544–66Mot + Tax73186058945343–63Tax75196256RCT
975544–66Bev + Tax78196464915544–66Mot + Tax73186058RCT
David W. Miles 2010 [9]2475527–76Bev + Tax187601671202415529–83Tax18952156135RCT
Robert Gray 2009 [10]3685629–84Bev + Tax223120244NA3545527–85Tax22399231NARCT
  1. Bev bevacizumab, Cap capecitabine, Vin vinorelbine, Cyc cyclophosphamide, Exm exemestane, Exr everolimus, Tre trebananib, Mot motesanib, RCTs randomized controlled trials, NA not applicable, n number of patients, Receptor Status hormone receptor status, ER+/PR+ estrogen receptor (ER) and/or progesterone receptor (PR) positive, TN triple negative, Chemo prior chemotherapy, Hormono prior hormonal therapy
\